Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence

BACKGROUND: We reported that Notch-1, a potent breast oncogene, is activated in response to trastuzumab and contributes to trastuzumab resistance in vitro. We sought to determine the preclinical benefit of combining a Notch inhibitor (γ-secretase inhibitor (GSI)) and trastuzumab in both trastuzumab-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Pandya, K, Meeke, K, Clementz, A G, Rogowski, A, Roberts, J, Miele, L, Albain, K S, Osipo, C
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2011
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3171020/
https://ncbi.nlm.nih.gov/pubmed/21847123
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.321
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados